Avenues to Precision Oncology

Until recently, the clinical management of cancer heavily relied on anatomical and histopathological criteria, with *ad hoc* guidelines directing the therapeutic choices in specific indications. In the last years, the development and therapeutic implementation of novel anticancer therapies significa...

Full description

Saved in:
Bibliographic Details
Main Author: Alexander Meisel
Format: Article
Language:English
Published: THE HEALTHBOOK COMPANY LTD. 2020-03-01
Series:healthbook TIMES. Oncology Hematology
Online Access:https://doi.org/10.36000/hbT.OH.2020.03.013
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Until recently, the clinical management of cancer heavily relied on anatomical and histopathological criteria, with *ad hoc* guidelines directing the therapeutic choices in specific indications. In the last years, the development and therapeutic implementation of novel anticancer therapies significantly improved the clinical outcome of cancer patients. Nonetheless, such cutting-edge approaches revealed the limitation of the one-size-fits-all paradigm. The newly discovered molecular targets can be exploited either as *bona fide* targets for subsequent drug development, or as tools to precision medicine, in the form of prognostic and/or predictive biomarkers. This article provides an overview of some of the most recent advances in precision medicine in oncology, with a focus on novel tissue-agnostic anticancer therapies. The definition and implementation of biomarkers and companion diagnostics in clinical trials and clinical practice are also discussed, as well as the changing landscape in clinical trial design.
ISSN:2673-2106